Suscribirse

EVALUATION OF ABNORMAL LIVER FUNCTION TESTS - 21/09/12

Doi : 10.1016/S0025-7125(05)70472-7 
Richard H. Moseley, MD
Gastroenterology Section, Ann Arbor Department of Veterans Affairs Medical Center; and the Division of Gastroenterology, University of Michigan Medical Center, Ann Arbor, Michigan 

Resumen

Laboratory determinations that reflect liver disease are commonly termed liver function tests. This is a misnomer because, for example, elevated serum aminotransferase and alkaline phosphatase activities are not indices of the degree of liver dysfunction but are only markers of liver injury. Even measures of specific hepatic functions, such as the serum albumin concentration, bilirubin concentration, and prothrombin time, can be affected by extrahepatic factors, such as nutritional state, hemolysis, and antibiotic use. Nevertheless, for the sake of discussion, the term liver function tests is used in this article to denote the battery of screening tests routinely available in most clinical laboratories, including serum aspartate (AST) and alanine (ALT) aminotransferase, serum alkaline phosphatase, serum total and direct bilirubin, serum total protein (with albumin and globulin fractionation), and prothrombin time. Beyond this minor semantic point, the evaluation of the patient with abnormal liver function tests is further complicated by the relative lack of well-defined diagnostic algorithms. Instead a systematic evaluation of the patient with abnormal liver function tests requires an understanding of the distinct patterns that the liver exhibits in response to injury as well as a working knowledge of the common liver disorders that present with a particular injury pattern. Once nonhepatic causes for any observed abnormalities are excluded(Table 1), the evaluation is facilitated by classification of liver injury into four major patterns: cholestatic, hepatocellular, immunologic, and infiltrative disease. Immunologic injury can present with either a cholestatic picture (if the bile ducts are the target of the immune response, as in primary biliary cirrhosis [PBC]) or a hepatocellular pattern of injury (if the hepatocyte is the primary target, as in viral and autoimmune hepatitis). The typical liver function test abnormalities seen in these types of liver injury are listed inTable 2. Although the rationale is provided subsequently during discussions of specific disorders, additional laboratory evaluation of any patient with prolonged elevation of serum aminotransferases, consistent with hepatocellular injury, most often should include the following:

•
Antinuclear antibody.
•
Serum ceruloplasmin.
•
Serum iron/total iron binding capacity.
•
Hepatitis B viral serology.
•
Antibody to hepatitis C virus (HCV).
•
Serum protein electrophoresis.

In contrast, the initial step in the evaluation of the patient with cholestatic indices (i.e., elevated serum alkaline phosphatase and bilirubin levels, with or without moderate elevations in serum ALT or AST) should be abdominal ultrasonography to assess the bile ducts, gallbladder, liver, and pancreas. An elevated serum bilirubin level in the absence of elevations in serum alkaline phosphatase or AST levels suggests underlying cardiac disease more than hepatobiliary disease.14 Isolated elevation of serum alkaline phosphatase, confirmed by serum leucine aminopeptidase (LAP), 5′-nucleotidase (5′-NT), or gamma-glutamyltranspeptidase (GGTP) to be hepatic in origin, is strongly suggestive of an infiltrative process, whether a localized or systemic granulomatous disorder or metastatic carcinoma to the liver. An approach to the patient with an elevated alkaline phosphatase level is proposed inFigure 1.

El texto completo de este artículo está disponible en PDF.

Esquema


 Address reprint requests to Richard H. Moseley, MD, Gastroenterology Section (111D), Department of Veterans Affairs Medical Center, 2215 Fuller Road, Ann Arbor, MI 48105


© 1996  W. B. Saunders Company. Publicado por Elsevier Masson SAS. Todos los derechos reservados.© 1995 
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 80 - N° 5

P. 887-906 - septembre 1996 Regresar al número
Artículo precedente Artículo precedente
  • PREFACE
  • PAUL MARTIN, LAWRENCE S. FRIEDMAN
| Artículo siguiente Artículo siguiente
  • EVALUATION OF THE SOLID HEPATIC MASS
  • Raymond A. Rubin, Donald G. Mitchell

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

@@150455@@ Voir plus

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2026 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.